Cargando…

Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma

BACKGROUND: Over the past four decades, outcomes for osteosarcoma patients have plateaued as there have been few emerging therapies showing clinical results. Thus, the identification of novel biomarkers and therapeutic strategies are urgently needed to address these primary obstacles in patient care...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Wenlong, Dean, Dylan C., Hornicek, Francis J., Spentzos, Dimitrios, Hoffman, Robert M., Shi, Huirong, Duan, Zhenfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222246/ https://www.ncbi.nlm.nih.gov/pubmed/32426053 http://dx.doi.org/10.1177/1758835920922055

Ejemplares similares

Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2021)

ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer
por: Feng, Wenlong, et al.
Publicado: (2020)

T‐LAK cell‐originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma
por: Thanindratarn, Pichaya, et al.
Publicado: (2021)

SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma
por: Guo, Tao, et al.
Publicado: (2022)

Exosomes promote pre-metastatic niche formation in ovarian cancer
por: Feng, Wenlong, et al.
Publicado: (2019)

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2018)

The role of extracelluar matrix in osteosarcoma progression and metastasis
por: Cui, Juncheng, et al.
Publicado: (2020)

T‐LAK cell‐originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma
por: Thanindratarn, Pichaya, et al.
Publicado: (2020)

Expression and Clinical Significance of High‐Mobility Group AT‐hook 2 (HMGA2) in Osteosarcoma
por: Cui, Juncheng, et al.
Publicado: (2022)

Potentials of Long Noncoding RNAs (LncRNAs) in Sarcoma: From Biomarkers to Therapeutic Targets
por: Min, Li, et al.
Publicado: (2017)

MicroRNA Involvement in Osteosarcoma
por: Kobayashi, Eisuke, et al.
Publicado: (2012)

Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067
por: Shen, Shen, et al.
Publicado: (2020)

Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11
por: Liao, Yunfei, et al.
Publicado: (2017)

Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential
por: Sun, Ranran, et al.
Publicado: (2016)

Inhibition of ATR-Chk1 signaling blocks DNA double-strand-break repair and induces cytoplasmic vacuolization in metastatic osteosarcoma
por: Li, Xiaoyang, et al.
Publicado: (2020)

Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11
por: Liao, Yunfei, et al.
Publicado: (2018)

Prognostic Significance of Cyclin E1 Expression in Patients With Chordoma: A Clinicopathological and Immunohistochemical Study
por: Wei, Ran, et al.
Publicado: (2020)

MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcoma
por: Lietz, Christopher E., et al.
Publicado: (2020)

sCLU as prognostic biomarker and therapeutic target in osteosarcoma
por: Ma, Jinfeng, et al.
Publicado: (2019)

Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells
por: Liao, Yunfei, et al.
Publicado: (2017)

MicroRNA-155 expression is independently predictive of outcome in chordoma
por: Osaka, Eiji, et al.
Publicado: (2015)

Transcriptional activation of CBFβ by CDK11(p110) is necessary to promote osteosarcoma cell proliferation
por: Feng, Yong, et al.
Publicado: (2019)

Advances in immune checkpoint inhibitors for bone sarcoma therapy
por: Thanindratarn, Pichaya, et al.
Publicado: (2019)

Correction to: Transcriptional activation of CBFβ by CDK11(p110) is necessary to promote osteosarcoma cell proliferation
por: Feng, Yong, et al.
Publicado: (2019)

Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma
por: Susa, Michiro, et al.
Publicado: (2009)

The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer
por: Zhou, Yubing, et al.
Publicado: (2016)

Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance
por: Liu, Tang, et al.
Publicado: (2016)

Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
por: Ryu, Keinosuke, et al.
Publicado: (2010)

An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets
por: Hill, Katherine E., et al.
Publicado: (2017)

CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma
por: Gao, Yan, et al.
Publicado: (2015)

Establishment and Characterization of a Novel Dedifferentiated Chondrosarcoma Cell Line DDCS2
por: Li, Xiaoyang, et al.
Publicado: (2021)

A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells
por: Duan, Zhenfeng, et al.
Publicado: (2014)

miR‐15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo
por: Duan, Zhenfeng, et al.
Publicado: (2016)

NSC23925, Identified in a High-Throughput Cell-Based Screen, Reverses Multidrug Resistance
por: Duan, Zhenfeng, et al.
Publicado: (2009)

Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma
por: Susa, Michiro, et al.
Publicado: (2010)

Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells
por: Zhang, Linlin, et al.
Publicado: (2015)

Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells
por: Chen, Hua, et al.
Publicado: (2017)

Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma
por: Li, Xiaoyang, et al.
Publicado: (2018)

Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients
por: Baron, Max, et al.
Publicado: (2023)

The mitotic regulator polo‐like kinase 1 as a potential therapeutic target for c‐Myc‐overexpressing canine osteosarcomas
por: Gola, Cecilia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dpajuog15sq67j4mstfmi9i8mk